Financial Performance - For the year ending December 31, 2025, the group's revenue from continuing operations increased by approximately 0.80% to approximately RMB 859 million, compared to RMB 852 million in 2024[2]. - The gross profit for the year ending December 31, 2025, was approximately RMB 143 million, down from RMB 169 million in 2024, resulting in a gross margin of approximately 16.69%, compared to 19.79% in 2024[2][4]. - The group reported a loss of approximately RMB 265 million for the year ending December 31, 2025, compared to a profit of approximately RMB 34 million in 2024[2][4]. - Basic and diluted loss per share from continuing operations was approximately RMB 14.41 for the year ending December 31, 2025, compared to RMB 8.54 in 2024[4]. - Total comprehensive loss for the year was approximately RMB 27.3 million, compared to a comprehensive income of RMB 0.53 million in 2024[5]. - Reported revenue from external customers for 2025 was RMB 85,900,000, a decrease of 5.6% from RMB 90,938,000 in 2024[27]. - Adjusted EBITDA for 2025 was a loss of RMB 7,261,000 compared to a profit of RMB 4,385,000 in 2024[27]. - Total comprehensive loss before tax for continuing and discontinued operations was RMB 26,997,000 in 2025, down from a profit of RMB 4,544,000 in 2024[27]. - The company reported a loss attributable to owners of RMB 22,040,000, compared to a profit of RMB 4,892,000 for the previous year[36]. - The company reported a substantial decrease in contract liabilities from RMB 4,147,000 in 2024 to RMB 588,000 in 2025[50]. Assets and Liabilities - Non-current assets decreased to approximately RMB 78 million as of December 31, 2025, from RMB 103 million in 2024[6]. - Current assets decreased to approximately RMB 344 million as of December 31, 2025, compared to RMB 366 million in 2024[6]. - The group's net assets decreased to approximately RMB 324 million as of December 31, 2025, from RMB 352 million in 2024[7]. - The group’s cash and cash equivalents were approximately RMB 299 million as of December 31, 2025, down from RMB 340 million in 2024[6]. - The group’s total liabilities decreased to approximately RMB 95.6 million as of December 31, 2025, from RMB 114.2 million in 2024[6]. - Total assets decreased to RMB 421,730,000 in 2025 from RMB 468,964,000 in 2024, reflecting a decline of 10.1%[27]. - Total liabilities decreased to RMB 97,630,000 in 2025 from RMB 117,358,000 in 2024, a reduction of 16.8%[27]. - Trade receivables decreased to RMB 3,678,000 in 2025 from RMB 9,561,000 in 2024, with a provision for losses of RMB 118,000 in 2025[42]. - The company’s total other receivables decreased to RMB 2,901,000 in 2025 from RMB 3,190,000 in 2024[42]. - Interest payable as of December 31, 2025, included RMB 4,676,000 related to convertible bonds, compared to RMB 3,100,000 in 2024[47]. Segment Performance - For the fiscal year ending December 31, 2025, the reported revenue from external customers for the pharmaceutical products segment was RMB 85,900,000, with an adjusted EBITDA loss of RMB (7,261,000)[16]. - The pharmaceutical products business incurred a loss of RMB 72.6 million during the reporting period, a decline from a profit of RMB 36.8 million in the previous year[62]. - The financing leasing business generated zero revenue during the reporting period, down from RMB 1.7 million in the previous year, due to the expiration of most existing contracts[63]. - The acquisition of a 51% stake in Beijing Hangyang Health Technology Co., Ltd. in May 2024 contributed approximately 68.12% to the total revenue of the pharmaceutical products business[61]. Expenses and Costs - Distribution costs for the year ended December 31, 2025, were approximately RMB 86 million, an increase of about RMB 23.5 million from RMB 62.5 million in 2024[73]. - Administrative expenses for the year ended December 31, 2025, were approximately RMB 287 million, an increase of about RMB 26.5 million from RMB 260 million in 2024[74]. - Financial costs for the year ended December 31, 2025, were approximately RMB 28.2 million, compared to RMB 22 million in 2024, mainly due to interest expenses from borrowings[76]. - Employee costs for continuing operations rose to RMB 23,199,000 in 2025 from RMB 19,509,000 in 2024, an increase of 18.0%[30]. - Research and development expenses increased to RMB 2,754,000 in 2025 from RMB 1,710,000 in 2024, an increase of 60.9%[30]. Corporate Governance and Compliance - The company is committed to high standards of corporate governance, ensuring the protection of shareholders' interests and long-term development[109]. - All directors confirmed compliance with the standard code of conduct for securities trading during the reporting period[111]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial reporting procedures and internal controls, ensuring compliance with relevant accounting standards[114]. - The company confirmed that it maintains sufficient public float as required by listing rules during the reporting period[116]. Capital Management - The company plans to implement a capital restructuring involving a share consolidation and capital reduction, effective from August 13, 2024, and February 3, 2025, respectively[55]. - The total issued and paid-up capital as of December 31, 2025, was RMB 1,421,000, a decrease from RMB 35,534,000 in 2024[53]. - The company proposed a capital reduction by canceling HKD 0.24 of the paid-up capital per share, reducing the par value of each issued share from HKD 0.25 to HKD 0.01, and splitting unissued shares into 25 new shares of HKD 0.01 each[106]. Legal Matters - The company received a civil judgment from the Beijing Fourth Intermediate People's Court on December 22, 2020, regarding a lawsuit involving Fujian Sanai Pharmaceutical Co., Ltd., claiming unpaid lease payments totaling RMB 33,855,032.69 and other associated costs[99]. - The judgment required Fujian Sanai to pay a total of RMB 67,371,546.21 in principal, RMB 57,636,357.78 in overdue interest, and RMB 2,904,331.80 in penalties, with the company and its former directors jointly liable for these amounts[102]. - The company filed an appeal against the judgment on January 22, 2021, arguing that the financing lease agreement and guarantees were invalid[101].
三爱健康集团(01889) - 2025 - 年度业绩